Research Interests
Pulmonary Hypertension
Heart Failure with Preserved Ejection Fraction
Heart Failure with Reduced Ejection Fraction
Precision Pharmacotherapy
Mobile Health
Selected Grants
ALLAY-HF
Clinical TrialPrincipal Investigator · Awarded by Alleviant Medical, Inc. · 2023 - 2030ARTISAN (REM-PH-418) A Phase 4, Prospective, Multicenter, Single-Arm Study of a Mean Pulmonary Artery Pressure-Targeted Approach with Early and Rapid Treprostinil Therapy to Reverse Right Ventricular Remodeling
Clinical TrialPrincipal Investigator · Awarded by Lung Biotechnology · 2023 - 2027REDUCE LAP-HF
Clinical TrialPrincipal Investigator · Awarded by Corvia Medical, Inc. · 2018 - 2026Automated acute pulmonary embolism assessment from CT
ResearchInvestigator · Awarded by Minnesota HealthSolutions · 2022 - 2025Spironolactone Initiation Registry Randomized Interventional Trial in Heart Failure with Preserved Ejection Fraction
ResearchPrincipal Investigator · Awarded by National Institutes of Health · 2018 - 2024Pulmonary Hypertension Databank and Electronic Health Record Analysis
ResearchPrincipal Investigator · Awarded by Clinetic, Inc · 2024 - 2024A Multicenter, Randomized, Double-blind, Placebo-controlled Study in Participants With Sarcoidosis-associated Pulmonary Hypertension (SAPH) to Assess the Efficacy and Safety of Oral Selexipag SPHINX
Clinical TrialPrincipal Investigator · Awarded by Janssen Research & Development, LLC · 2021 - 2023Complexa Prime Open Label extention
Clinical TrialPrincipal Investigator · Awarded by Complexa, Inc · 2020 - 2022Multicenter Exercise Tolerance Evaluation of Omecamtiv Mecarbil Related to Increased Contractility in Heart Failure
Clinical TrialPrincipal Investigator · Awarded by Cytokinetics, Inc. · 2019 - 2021PAH trial of GB002
Clinical TrialPrincipal Investigator · Awarded by Gossamer Bio · 2019 - 2021Complexa PRIME - CXA-10-301
Clinical TrialPrincipal Investigator · Awarded by Complexa, Inc · 2018 - 2020External Relationships
- Diastol
- United Therapeutics Corp.
This faculty member (or a member of their immediate family) has reported outside activities with the companies, institutions, or organizations listed above. This information is available to institutional leadership and, when appropriate, management plans are in place to address potential conflicts of interest.